Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | BACE1 | P56817 | 1/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | RORC | P51449 | 1/20 | 0.47 |
| ▸ | VNN1 | O95497 | 1/20 | 0.47 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3235987 | 0.83 | BACE1 (0.60) | LMNANPC1RAB9ABACE1MEN1 | |
| SCHEMBL3202382 | 0.80 | LMNA (0.53) | LMNANPC1RAB9ABACE1TRPV1 | |
| SCHEMBL9849523 | 0.79 | MEN1 (0.70) | LMNANPC1RAB9ABACE1MEN1 | |
| SCHEMBL3196417 | 0.79 | P2RX7 (0.49) | NPC1RAB9ATRPV1MEN1KMT2A | |
| SCHEMBL3216508 | 0.78 | NPC1 (0.53) | LMNANPC1RAB9ABACE1TRPV1 | |
| SCHEMBL5177697 | 0.78 | BACE1 (0.57) | LMNANPC1RAB9ABACE1MEN1 | |
| SCHEMBL1397439 | 0.78 | ROCK1 (0.54) | LMNAMEN1KMT2AMAPTVNN1 | |
| SCHEMBL5176613 | 0.78 | LMNA (0.61) | LMNANPC1RAB9ABACE1MEN1 | |
| SCHEMBL3216761 | 0.77 | KMT2A (0.62) | NPC1RAB9ATRPV1MEN1KMT2A | |
| SCHEMBL5178510 | 0.77 | BACE1 (0.56) | LMNANPC1RAB9ABACE1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674815-B2 | Heteroaryl and benzyl amide compounds | HOFFMANN-LA ROCHE INC. (US) | 2010-03-09 | — | — | US | claimed |
| US-7674815-B2 | Heteroaryl and benzyl amide compounds | HOFFMANN-LA ROCHE INC. (US) | 2010-03-09 | — | — | US | disclosed |
| EP-2007726-A2 | BENZAMIDE AND HETEROARENE DERIVATIVES AS CETP INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007090749-A2 | BENZAMIDE AND HETEROARENE DERIVATIVES AS CETP INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-16 | — | — | WO | disclosed |
| US-20070185113-A1 | Heteroaryl and benzyl amide compounds | HOFFMANN-LA ROCHE INC. | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185113-A1 | Heteroaryl and benzyl amide compounds | CYP2C19, CYP2C9, CYP3A43 | LMNA 1780/4885NPC1 115/4885RAB9A 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.